Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Closed 01-13 16:00:00 EST

8.04

-0.06

-0.80%

盘后8.08

+0.04+0.50%

19:20 EST

High8.21	Low7.95	Vol807.99K
Open8.05	D1 Closing8.11	Amplitude3.22%
Mkt Cap630.68M	Tradable Cap401.75M	Total Shares78.44M
T/O6.50M	T/O Rate1.62%	Tradable Shares49.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":8.04,"timestamp":1768338000000,"preClose":8.105,"halted":0,"volume":807987,"hourTrading":{"tag":"盘后","latestPrice":8.0801,"preClose":8.04,"latestTime":"19:20 EST","volume":16733,"amount":134625.1964,"timestamp":1768350005818},"delay":0,"floatShares":49968589,"shares":78443334,"eps":-3.467754,"marketStatus":"Closed","change":-0.065,"latestTime":"01-13 16:00:00 EST","open":8.05,"high":8.2062,"low":7.945,"amount":6503392.020534,"amplitude":0.032227,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.467754,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":8.105,"preHourTrading":{"tag":"盘前","latestPrice":8.1,"preClose":8.105,"latestTime":"09:28 EST","volume":161,"amount":1306.8645310000002,"timestamp":1768314481151},"postHourTrading":{"tag":"盘后","latestPrice":8.0801,"preClose":8.04,"latestTime":"19:20 EST","volume":16733,"amount":134625.1964,"timestamp":1768350005818},"volumeRatio":0.732734,"impliedVol":0.2423,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/REPL/wiki","defaultTab":"wiki","newsList":[{"id":"2592911602","title":"Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911602","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911602?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:27","pubTimestamp":1765974444,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. ( NASDAQ:REPL ) shareholders might have a reason to worry after multiple insiders sold their...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/insiders-at-replimune-group-sold-us766k-in-stock-alluding-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/insiders-at-replimune-group-sold-us766k-in-stock-alluding-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2590541989","title":"Replimune Group Director Kapil Dhingra Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541989","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541989?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:31","pubTimestamp":1765488684,"startTime":"0","endTime":"0","summary":"Kapil Dhingra, Director at Replimune Group Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3j96VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Replimune Group Director Kapil Dhingra Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2589846830","title":"Replimune CEO Sushil Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589846830","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589846830?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:30","pubTimestamp":1764883851,"startTime":"0","endTime":"0","summary":"Sushil Patel, Chief Executive Officer and Director of Replimune Group Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLbXpL3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Replimune CEO Sushil Patel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU1934455277.USD","LU1430594728.SGD","MRK","SGXZ57979304.SGD","VIGL","QID","QLD","VRNA","LU2089984988.USD","NVIW.SI","SQQQ","SG9999014559.SGD","BK4559","LU0289739699.SGD","BK4505","QURE","BK7067",".IXIC","TQQQ","CELC","REPL","IE00B19Z3B42.SGD","LU1929549753.HKD","PSQ","LU0265550359.USD","IE000M9KFDE8.USD","LU1116320901.HKD","USAW.SI","LU2324357040.USD","USJW.SI","LU0098860793.USD","LU1037948897.HKD","LU0985320562.USD","MNQmain","TSYW.SI","LU2023250504.SGD","CSL.AU","BK4532","LU0861579265.USD","LU0265550946.USD","IE00BN8TJ469.HKD","IE00BSNM7G36.USD","NVS","RNA","LU1057294990.SGD","LU0238689110.USD","NQmain","LU1934455194.USD","PFE"],"gpt_icon":1},{"id":"2584692672","title":"Replimune Group Q2 Net Income USD -83.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692672","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692672?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:54","pubTimestamp":1763571272,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Replimune Group Q2 operating expenses USD 84.291 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:32:33.287 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD7D6mPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2581988758","title":"Replimune Group Inc  expected to post a loss of 75 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988758","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988758?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:17","pubTimestamp":1762532225,"startTime":"0","endTime":"0","summary":"Replimune Group Inc  expected to post a loss of75cents a share - Earnings Preview Replimune Group Inc REPL.OQ REPL.O is expected to  show no change in quarterly revenue when it reports  results  for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"1105330981","title":"Stock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330981","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105330981?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:59","pubTimestamp":1762531142,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["REPL"],"gpt_icon":0},{"id":"2581886171","title":"Replimune Group Inc. publishes study on anti-PD-1-failed NMSC and MSI-H/dMMR solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886171?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:10","pubTimestamp":1762524602,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. published a document related to clinical research in oncology, specifically focusing on patients with anti-PD-1-failed non-melanoma skin cancer  and anti-PD-1-failed MSI-H/dMMR solid tumors. The document provides information about study design, response rates assessed by blinded independent central review using RECIST 1.1, and additional clinical trial details. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL2TNdgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581041624","title":"Replimune Group Inc : Files for Mixed Shelf Offering of up to $250 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581041624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581041624?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:47","pubTimestamp":1762469226,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI1RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581095871","title":"Replimune Q2 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095871?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:14","pubTimestamp":1762434844,"startTime":"0","endTime":"0","summary":"Replimune Q2 net loss widensOverviewReplimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last yearCash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025OutlookReplimune ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2581377093","title":"Replimune Group reports fiscal Q2 R&D expenses of $57.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581377093","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581377093?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:01","pubTimestamp":1762434102,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. reported research and development expenses of $57.9 million for the fiscal second quarter ended September 30, 2025, up from $43.4 million for the same period in 2024. The increase was mainly due to higher direct research costs related to the IGNYTE-3 confirmatory study and other study costs, as well as increased personnel-related expenses in preparation for a potential commercial launch of RP1. Cash, cash equivalents, and short-term investments totaled $323.6 million as of September 30, 2025, compared to $483.8 million as of March 31, 2025. The company announced the FDA accepted the BLA resubmission for RP1 for advanced melanoma, with a PDUFA target action date of April 10, 2026. Replimune expects its current cash position to fund operations into late Q4 2026, including potential commercialization of RP1 in skin cancers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbN6Snw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","BK4588","BK4139","BK4112","IE00BKPKM429.USD","REPL","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581303093","title":"BRIEF-Replimune Group Q2 Net Income USD -83.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581303093","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581303093?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434050,"startTime":"0","endTime":"0","summary":"BRIEF-Replimune Group Q2 Net Income USD -83.1 Million\n\n\nNov 06 (Reuters) - Replimune Group Q2 operating expenses USD 84.291 million.\n\nQ2 operating income USD -84.291 million\nQ2 basic EPS USD -0.9\nQ2 cash & investments USD 323.6 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXDF7B3A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581093351","title":"Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093351?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434010,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA30V3PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581398093","title":"Replimune Group Q2 Cash & Investments USD 323.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581398093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581398093?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXDF7B3A:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2581093824","title":"Replimune Group Q2 Basic EPS USD -0.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093824?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXDF7B3A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2578622262","title":"Replimune Group Rise After HC Wainwright Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622262","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578622262?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:42","pubTimestamp":1761590572,"startTime":"0","endTime":"0","summary":"Replimune Group  shares were up more than 4% in recent Monday trading after HC Wainwright upgraded the stock to buy from neutral, with a price target of $12.Trading volume stood at over 2.5 million shares, versus the daily average of 9.7 million.Price: 9.18, Change: +0.38, Percent Change: +4.26","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2578643270","title":"HC Wainwright Upgrades Replimune Group to Buy From Neutral, Price Target is $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2578643270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578643270?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:51","pubTimestamp":1761565901,"startTime":"0","endTime":"0","summary":"Replimune Group (REPL) has an average rating of overweight and mean price target of $10.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2578648421","title":"Replimune Group Raised to Buy From Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648421?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:30","pubTimestamp":1761564600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 07:30 ET (11:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2578820612","title":"Replimune Group Inc : H.c. Wainwright Raises to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2578820612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578820612?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:21","pubTimestamp":1761560508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nFWN3W80WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"1177309908","title":"Stock Track | Replimune Group Plunges 5.19% Despite Analyst Upgrades, Barclays' Low Target a Likely Factor","url":"https://stock-news.laohu8.com/highlight/detail?id=1177309908","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177309908?lang=en_us&edition=fundamental","pubTime":"2025-10-21 21:52","pubTimestamp":1761054755,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. (REPL) experienced a surprising 5.19% plummet in Tuesday's pre-market trading, despite receiving several positive analyst upgrades. This contradictory movement has left investors...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["REPL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0374},{"period":"1month","weight":-0.2038},{"period":"3month","weight":0.8632},{"period":"6month","weight":-0.3583},{"period":"1year","weight":-0.2672},{"period":"ytd","weight":-0.1662}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.000059},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.070613},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.10067},{"month":4,"riseRate":0.571429,"avgChangeRate":0.118692},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.048711},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}